References
- 1. Goldhaber SZ. Pulmonary Embolism. N Engl J Med. 1998;339:93-104.10.1056/NEJM199807093390207
- 2. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. 2002;347:1131-1132. doi:10.1016/0033-0620(91)90009-B.10.1016/0033-0620(91)90009-B
- 3. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006;97:127-129. doi: http://dx.doi.org/10.1016/j.amjcard.2005.07.117.10.1016/j.amjcard.2005.07.117
- 4. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511. doi:10.1016/0140-6736(93)90274-K.10.1016/0140-6736(93)90274-K
- 5. Konstantinides S, Tiede N, Kasper W, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82(8):966-970. doi: http://dx.doi.org/10.1016/S0002-9149(98)00513-X.10.1016/S0002-9149(98)00513-X
- 6. Fukuda I, Taniguchi S, Suzuki Y, et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg. 2011;91(3):728-732. doi: 10.1016/j.athoracsur.2010.10.086.10.1016/j.athoracsur.2010.10.086
- 7. Kuo WT, Gould MK, Hofmann LV, et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009;20(11):1431-1440. doi: 10.1016/j. jvir.2009.08.002.
- 8. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1(7138):1309-1312.
- 9. Kanter DS, Mikkola KM, Goldhaber SZ, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111(5):1241-1245. doi:10.1378/chest.111.5.124110.1378/chest.111.5.1241
- 10. Levine MN, Goldhaber SZ, Califf RM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest. 1995;108(4 Suppl):291S-301S.10.1378/chest.108.4_Supplement.291S
- 11. Mikkola KM, Patel SR, Goldhaber SZ, et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J. 1997;134(1):69-72. doi: http://dx.doi.org/10.1016/S0002-8703(97)70108-X.10.1016/S0002-8703(97)70108-X
- 12. Sharifi M, Bay C, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. 2013;111(2):273-7. doi: 10.1016/j.amjcard.2012.09.027.10.1016/j.amjcard.2012.09.02723102885
- 13. Wang C, Zhai Z, Shen YH, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254-62. doi: 10.1378/chest.09-0765.10.1378/chest.09-0765712699419741062
- 14. Engelberger RP, Kucher N, et al. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J. 2014;35:758-764. doi: http://dx.doi.org/10.1093/eurheartj/ehu029.10.1093/eurheartj/ehu02924497337
- 15. Kucher N, Boekstegers P, Baumgartner I, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circ. 2014;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544.10.1161/CIRCULATIONAHA.113.00554424226805